Analyst firms · Raymond James · VCYT
Raymond James VCYT price target and rating history
Veracyte Inc. (VCYT) · Health Care
Raymond James rates Veracyte Inc. (VCYT) Mkt Perform with a $34 price target, as of its latest action on Jan 18, 2023. It has published 4 rating actions on VCYT since June 2021, including 0 upgrades and 1 downgrade. Across 5 firms with a VCYT price target in the last 12 months, the median target is $48.
- Current rating
- Mkt Perform
- Price target
- $34
- Median target, all firms
- $48
- Actions on VCYT
- 4
Raymond James price target on VCYT
Every Raymond James rating on VCYT
- Jan 18, 2023
- Mar 1, 2022
- Nov 10, 2021
- Jun 28, 2021
How other firms rate VCYT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Market Perform | $35 | Nov 5, 2026 |
| Piper Sandler | Overweight | $66 | Jul 15, 2026 |
| Wolfe Research | Outperform | $55 | Jun 2, 2026 |
| Jefferies | Buy | $45 | Apr 13, 2026 |
| Morgan Stanley | Underweight | $48 | Dec 2, 2025 |
Questions about Raymond James and VCYT
- What is Raymond James's price target for VCYT?
- Raymond James's latest stated price target for Veracyte Inc. (VCYT) is $34, from its action on Mar 1, 2022.
- What is Raymond James's rating on VCYT?
- Raymond James rates VCYT Mkt Perform, a neutral rating, as of Jan 18, 2023.
- When did Raymond James last change its view on VCYT?
- On Jan 18, 2023, Raymond James downgrades to Mkt Perform from Outperform.
- How does Raymond James's VCYT target compare with other analysts?
- Across 5 firms with a VCYT price target in the last 12 months, the median target is $48.
More VCYT rating histories
All Raymond James ratingsVCYT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.